Merck's (MRK) Pembrolizumab Nears Early FDA Approval
Tweet Send to a Friend
Merck & Co. (NYSE: MRK) is nearing regulatory approval of its highly-anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma.Reuters ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE